Home > Offer to Sell > Pharmaceuticals and Biochemicals > Biochemicals and biotech products > Pasireotide
Pasireotide
Inquiry
| Post Date: | Aug 01,2017 |
| Expiry Date: | Aug 01,2018 |
| Detailed Description: |
Cas No. :396091-73-9
Payment Method: T/T Full Name：Pasireotide/p> Cas No：396091-73-9 Molecular Formular: C58H66N10O9 Molecular Weight: 1047.21 Sequence：Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl] Purity：≥98.0% Application field: Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. |
| CAS Registry Number: | 396091-73-9 |
| Molecular Structure: | 
|
| Company: | Zhejiang Peptites Biotech Co., Ltd [ China ] |
| Contact: | Zoe |
| Tel: | +8657186698660 |
| Fax: | |
| Email: | sales1@peptide-manufacturer.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
